Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Coelho, T; Yarlas, A; Waddington-Cruz, M; White, MK; Kessler, AS; Lovley, A; Pollock, M; Guthrie, S; Ackermann, EJ; Hughes, SG; Karam, C; Khella, S; Gertz, M; Merlini, G; Obici, L; Schmidt, HH; Polydefkis, M; Dyck, PJB; Brannagan, TH; Conceicao, I; Benson, MD; Berk, JL

Yarlas, A (corresponding author), Optum, 1301 Atwood Ave, Johnston, RI 02919 USA.

JOURNAL OF NEUROLOGY, 2020; 267 (4): 1070

Abstract

Objective To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi (TM)) ......

Full Text Link